重组人脑利钠肽治疗心肌梗死后难治性心力衰竭的疗效评价

目的评价重组人脑利钠肽（商品名新活素）在心肌梗死后难治性心力衰竭治疗中的应用效果。方法选取医院心内科2012年3月至2013年3月收治的心肌梗死后难治性心力衰竭患者30例，应用随机数字表法将患者分为对照组和观察组，各15例。对照组患者接受常规治疗，观察组患者加用新活素治疗，比较两组的临床疗效、血浆c反应蛋白、N末端B型脑钠肽前体（NT—proBNP）、每搏输出量（SV）和左室射血分数（LVEF）情况。结果观察组患者治疗总有效率达100．00％，显著高于对照组的66．67％（P〈0．05）；观察组患者血浆c反应蛋白含量为（2．12±0．98）mg／L、NT—proBNPB含量为（48．194±20．15）pg／L，均明显低于对照组的（3．994±1．11）mg／L和（92．734±25．32）pg／L（P〈0．05）；观察组患者SV为（78．394±5．64）mL和LVEF为（53．81±6．26）％，明显高于对照组的（66．434-6．55）mL和（42．29±5．78）％（P〈0．05）。结论脑利钠肽治疗心肌梗死后难治性心力衰竭患者临床疗效确切，具有安全、高效、不良反应少等特点。

Clinical Efficacy of Recombinant Human Brain Natriuretic Peptide in Treating Refractory Heart Failure after Myocardial Infarction

Objective To analyze the application effect of recombinant human brain natriuretic peptide （Xinhuosu） in treating refractory heart failure after myocardial infarction. Methods Thirty patients with refractory heart failure after myocardial infarction in the cardiol- ogy department admitted to our hospital from March 2012 to March 2013 were divided into the control group and the observation group according to the random number table, 15 cases in each group. The control group received the conventional treatment, while the observation group was added with recombinant human brain natriuretic peptide. The clinical efficacy, plasma C- reactive protein（CRP）, NT- proBNP, cardiac stroke volume （SV） and left ventricular ejection fraction （LVEF） were compared between the two groups. Results The total effective rate in the observation group was 100.00%, which was significantly higher than 66.67% in the control group（ P 〈 0. 05）; plasma CRP in the observation group was （2. 12 ± 0. 98）mg/L, NT- proBNP B- type natriuretic peptide levels was （48.19± 20. 15 ） pg ! L, which were significantly lower than （ 3.99 ± 1.11 ） mg / L and （ 92.73 ± 25.32） pg / L in the control group （ P 〈 0.05）; the SV and LVEF in the observation group were （78.39 ±5.64）mL and （53.81 ±6.26）% respectively, which were sig- nificantly higher than （66.43±6.55）mL and （42.29±5.78）% in the control group（P〈0.05）.Conclusion Xinhuosu has definite clinical effect in treating refractory heart failure after myocardial infarction and has the advantages of safety, efficiency and fewer adverse reactions.